NASDAQ · Biotechnology

PDS Biotechnology Corporation (PDSB) Stock

$1.38 +35.29% NASDAQ: PDSB Healthcare

Valuation

MetricValue
Price$1.38
Market Cap$77.17M
P/E Ratio-1.59
P/B Ratio-15.86
P/S Ratio0.00
EPS (TTM)$-0.74
52-Week High$1.55
52-Week Low$0.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-708.20%
ROA-382.32%
ROCE779.57%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-1.22
Current Ratio3.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-21.0M$-42.0M$-43.0M$-36.0M$-32.0M
Net Profit$-17.0M$-41.0M$-43.0M$-38.0M$-34.0M
EPS$-0.66$-1.43$-1.39$-1.03$-0.74
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$67.0M$77.0M$59.0M$45.0M$30.0M
Total Liabilities$4.0M$33.0M$33.0M$26.0M$21.0M
Cash$65.0M$74.0M$57.0M$42.0M$27.0M
Borrowings$0$23.0M$24.0M$22.0M$17.0M

Latest News

Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher Zacks · Jun 10, 2026 PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ... GuruFocus.com · May 13, 2026 PDS Biotechnology Q1 Earnings Call Highlights MarketBeat · May 13, 2026 PDS Biotechnology Corporation Q1 2026 Earnings Call Summary Moby · May 13, 2026 PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript Benzinga · May 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-26.0M$-34.0M$-35.0M$-28.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$-1.0M$0$1.0M$0
Net Cash Flow$36.0M$9.0M$-17.0M$-15.0M$-15.0M
Free Cash Flow$-12.0M$-26.0M$-34.0M$-35.0M$-28.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.04
EV / EBITDA-2.06
FCF Yield-29.42%
Quick Ratio0.57
Interest Coverage-4.18
Return 1Y-37.11%
Return 3Y-85.66%
Return 5Y-92.33%

Ownership

Insiders Held1.51%
Institutions Held9.17%
Institutions Float Held9.31%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC1,631,0892026-03-31
Geode Capital Management, LLC660,2282026-03-31
Blackrock Inc.554,0482026-03-31
Vanguard Fiduciary Trust Co307,3112026-03-31
BLAIR WILLIAM & CO/IL300,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVSAnnovis Bio, Inc. $1.21 +3.42% -0.67 $51.48M 0.00%
ATNMActinium Pharmaceuticals, Inc. (Delaware) $1.10 +1.85% 3.25 $34.51M 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%
INMBINmune Bio Inc. $1.87 +1.91% -2.81 $49.58M 0.00%
KZR $7.29 +0.00% -0.96 $53.86M 0.00%

About PDS Biotechnology Corporation

PDS Biotechnology Corporation is led by CEO Frank K. Bedu-Addo, employs 24 people, headquartered in US, publicly traded since 2015.

PDS Biotechnology Corporation (PDSB) stock trades at $1.38 with a market capitalization of $77.17M. The stock is valued at a price-to-earnings (P/E) ratio of -1.59, price-to-book of -15.86, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.20 and $1.55, and currently trades 11.0% below its 52-week high.

On profitability, PDS Biotechnology Corporation generates a return on equity (ROE) of -708.20%, return on capital employed of 779.57%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides